Home Companies MRNA
Healthcare · Biotechnology · Peer Analysis

Moderna, Inc. (MRNA) — Structural Peer Analysis

Moderna, Inc. ranks among the weaker positions in its peer group, with a relatively even profile across the main dimensions. That creates a tension: current price behavior looks stronger than the structural profile would suggest.

Updated 2026-08-16 · SP500
Current market signal · 2026-08-07
Profile and price weak

Discounted for Pipeline Uncertainty, Not Profitability

52w drawdown -27.7% · 21d vs sector -20.1%

View MRNA situation → All companies with this signal
ENTRY TODAY
Neutral price zonebelow norm
TODAY (5y history)36th pct today
0th50th100th
Today the stock sits in a broadly neutral part of its long-term range and its multiple is below its own norm.
Describes where today's entry sits in the stock's own long-term price and valuation history. Descriptive only. Not investment advice.
Dimension Profile

Peer-relative scores, weakest to strongest

Weakest Stability 3
Bottom 25% of peers
Weak Growth 8
Bottom 25% of peers
Moderate Profitability 15
Bottom 25% of peers
Strongest Valuation 30
Below median
Peer-Relative Score
16
Peer-Score
Weak peer position
Signal qualitylow
Structural Read

Discounted for Pipeline Uncertainty, Not Profitability

Moderna develops mRNA-based vaccines and therapeutics focused on infectious diseases and rare conditions.

The market prices Moderna on the hope of future pipeline success, not on sustainable profitability like established biotech firms. With an operating margin of -44.7% and ROIC at -18.2%, Moderna is posting deep losses and persistent capital destruction. Its pipeline will not generate significant revenue until after 2028, so investors treat the company as a late-stage breakthrough bet rather than a near-term earnings story. In biotech, near-term product approvals and margin strength are key; Moderna lacks both in the current cycle, which leads the market to consistently price the stock at a steep discount relative to peers with visible profitability and product momentum. The market refrains from assigning a premium or factoring in near-term AI advances or pipeline developments until tangible revenues appear. Only a successful FDA approval for mRNA-1010 or an accelerated pipeline breakthrough before 2028 could shift the market’s valuation logic.

AssetNext · 2026-08-05 · Rule-based and descriptive. Not investment advice.

Explore how MRNA compares across its peer group

Break down MRNA's position across all dimensions with the full interactive tool.

Open full peer comparison →
Compare MRNA with peers

This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.